Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Archives of General Surgery(Electronic Edition) ›› 2018, Vol. 12 ›› Issue (05): 314-318. doi: 10.3877/cma.j.issn.1674-0793.2018.05.007

Special Issue:

• Original Article • Previous Articles     Next Articles

Diagnostic value and mechanism study of microRNA-301 in hepatocellular carcinoma

Kun He1,(), Zemin Hu1, Jiahou Ruan1, Ruiqin Huang1, Qijie Luo1   

  1. 1. Department of Hepatobiliary Surgery, Zhongshan People’sHospital Affiliated to Sun Yat-sen University, Zhongshan City People’s Hospital, Zhongshan 528403, China
  • Received:2017-12-16 Online:2018-10-01 Published:2018-10-01
  • Contact: Kun He
  • About author:
    Corresponding author: He Kun, Email:

Abstract:

Objective

To explore the diagnostic value of microRNA-301 in hepatocellular carcinoma.

Methods

From January 2014 to July 2015, preoperative serum specimens of fifity-two patients with hepatocellular carcinoma in Zhongshan City Peoples Hospital were collected as experimental group. Serum samples from 38 healthy subjects were collected as control. The level of microRNA-301 gene expression in two groups was measured by quantitative PCR and compared with independent sample t test. The ROC curve was used to explore the diagnostic truncation value and effectiveness. The relationship between the expression level of microRNA-301 and the clinicopathological parameters of hepatocellular carcinoma were preliminary analyzed. Correlation analysis and variance analysis were used to verify association of microRNA-301 level with Barcelona staging in hepatocellular carcinoma.

Results

(1) The relative expression level of serum microRNA-301 in the experimental group was 0.035±0.014, which was significantly higher than that in the control group (0.021±0.012), the difference was statistically significant (t=4.793, P<0.001). (2) The best cut off value of ROC curve was 0.203 850, sensitivity was 86.5%, specificity was 63.2%, the area under ROC curve was 0.77 (P<0.01), and the diagnostic effectiveness was certain. (3) The relative expression level of microRNA-301 was not significantly correlated with age, sex and tumor size (P=0.409, 0.236, 0.096), while correlated with Barcelona stage, portal vein tumor thrombus, AFP level and HBsAg positivity (P=0.001, 0.017,0.007, <0.001). Barcelona staging had relatively large effect on prognosis, and the correlation coefficient of Pearson was 0.825 (P<0.001). (4) There were 7, 25 and 20 cases in the early, middle and late stages of Barcelonastaging, respectively. One-way ANOVA analysis showed that there was no significant difference in the relative expression level of microRNA-301 between the early and middle stages of patients (P=0.545), while the late stage was significantly higher than the early and middle stages (P=0.006, <0.001).

Conclusions

microRNA-301, as an oncogene microRNA, is up-regulated in the serum of patients with hepatocellular carcinoma. The relative expression level of microRNA-301 is associated with Barcelona staging, portal vein tumor thrombus, AFP and HBsAg, and has certain diagnostic value for hepatocellular carcinoma.

Key words: Carcinoma, hepatocellular, MicroRNAs, MicroRNA-301, Diagnostic value

京ICP 备07035254号-20
Copyright © Chinese Archives of General Surgery(Electronic Edition), All Rights Reserved.
Tel: 020-87331056 E-mail: pwwxcma2007@126.com
Powered by Beijing Magtech Co. Ltd